<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509832</url>
  </required_header>
  <id_info>
    <org_study_id>EDC-2420</org_study_id>
    <nct_id>NCT02509832</nct_id>
  </id_info>
  <brief_title>COOL AMI EU Pilot Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction</brief_title>
  <official_title>COOL-AMI EU PILOT TRIAL: A Multicenter, Prospective, Randomized Controlled Trial To Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With ACUTE MYOCARDIAL INFARCTION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZOLL Circulation, Inc., USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ZOLL Circulation, Inc., USA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      COOL AMI EU Pilot Trial: A Multicenter, Prospective, Randomized Controlled Trial to Assess
      Cooling as an adjunctive Therapy to Percutaneous Intervention in Patients with Acute
      Myocardial Infarction.

      Evaluate the retention of subjects after integrating therapeutic hypothermia using the ZOLL
      Proteus IVTM System into existing STEMI treatment protocols for subjects who present with
      acute anterior myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the retention of subjects after integrating therapeutic hypothermia using the ZOLL
      Proteus IVTM System into existing STEMI treatment protocols for subjects who present with
      acute anterior myocardial infarction.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of all subjects who complete the follow-up and cMR imaging requirements at 30-day follow up period</measure>
    <time_frame>30 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Anterior Infarct Size (IS) as assessed by Cardiac Magnetic Resonance (cMR) at 4 - 6 days following the index procedure for subjects in Test and Control Arms</measure>
    <time_frame>4 - 6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Cooling + PCI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCI only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cooling + PCI</intervention_name>
    <description>Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)</description>
    <arm_group_label>Cooling + PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCI only</intervention_name>
    <description>Standard of Care for PCI</description>
    <arm_group_label>PCI only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All Inclusion Criteria must be answered YES for subject to be eligible for trial Inclusion
        Criteria:

          1. ≥ 18 years of age.

          2. symptoms consistent with AMI (chest pain, unresponsive to nitroglycerin, ≥ 30 minutes
             and &lt; 6 hours.

          3. Anterior MI with ST-segment elevation of 0.2 mV in two or more anterior contiguous
             precordial leads.

          4. Eligible for PCI.

          5. Opportunity for at least 10 minutes of cooling with the Proteus IVTM System prior to
             PCI.

          6. Written, informed consent to participate in this clinical trial.

        Exclusion Criteria:

        All Exclusion Criteria must be answered NO for subject to be eligible for trial inclusion.

          1. Previous myocardial infarction.

          2. Cardiogenic shock (systolic blood pressure [SBP] &lt;80 mmHg and non-responsive to
             fluids, or SBP &lt;100 mmHg with vasopressors, or requirement for an intra-aortic balloon
             pump [IABP]).

          3. Resuscitated cardiac arrest, atrial fibrillation, or Killip risk stratification class
             II through IV

          4. Aortic dissection or requires an immediate surgical or procedural intervention other
             than PCI

          5. Congestive Heart Failure (CHF), hepatic failure, end- stage kidney disease or severe
             renal failure (clearance &lt; 30ml/min/1.73m2).

          6. Fever (temperature &gt; 37.5 °C) or infection with fever in the last 5 days.

          7. Previous CABG.

          8. Stroke within 90 days of admission.

          9. Cardio-pulmonary decompensation present or imminent

         10. Contraindications to hypothermia, such as patients with known hematologic dyscrasias
             which affect thrombosis (e.g., cryoglobulinemia, sickle cell disease, serum cold
             agglutinins) or vasospastic disorders (such as Raynaud's or thromboangitis obliterans)

         11. Hypersensitivity or contraindication to aspirin, heparin, or sensitivity to contrast
             media, which cannot be adequately pre-medicated.

         12. History of bleeding diathesis, coagulopathy, cryoglobulinemia, sickle cell anemia, or
             will refuse blood transfusions.

         13. Height of &lt;1.5 meters (4 feet 11 inches).

         14. Hypersensitivity to buspirone hydrochloride or Pethidine (Meperidine) and/or treatment
             with a monoamine oxidase inhibitor in the past 14 days.

         15. History of severe hepatic or renal impairment, untreated hypothyroidism, Addison's
             disease, benign prostatic hypertrophy, or urethral stricture that in the opinion of
             the physician would be incompatible with Pethidine administration.

         16. Inferior Vena Cava filter in place (IVC).

         17. The patient has a pre-MI life expectancy of &lt;1 year due to underlying medical
             conditions or pre-existing co-morbidities.

         18. Known, unresolved history of drug use or alcohol dependency, or lacks the ability to
             comprehend or follow instructions.

         19. Currently enrolled in another investigational drug or device trial that has not
             completed the primary endpoint.

         20. Apprehension or unwilling to undergo the required MRI imaging at follow-up, has a
             documented or suspected diagnosis of claustrophobia, or has Gadolinium allergy

         21. Received thrombolytic therapy en route to the hospital

         22. Clinical evidence of spontaneous reperfusion as observed symptomatically and/ or from
             ECG findings (partial or complete ST resolution in ECG before randomization) upon
             admission

         23. Vulnerable subject, for instance, a person in detention (i.e., prisoner or ward of the
             state)

         24. Female who is known to be pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Holzer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik für Notfallmedizin Allgemeines Krankenhaus der Stadt Wien</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marko Noc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Ljubljana Slovenia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für Notfallmedizin Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Estonia Medical Center</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Balatonfüred</name>
      <address>
        <city>Balatonfüred,</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical and Health Science Center University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Institute University of Pecs</name>
      <address>
        <city>Pecs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Cardiology, Department of Interventional Cardiology &amp; Angiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Center for Heart Diseases</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University in Łódź, Bieganski Hospital</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia Head of Department for invasive diagnostics (Division of Cardiology)</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital Center Zemun</name>
      <address>
        <city>Zemun</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital Lund University</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essex Cardiothoracic Centre, Anglia Ruskin University</name>
      <address>
        <city>Basildon</city>
        <state>Essex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovenia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2015</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic Hypothermia (TH)</keyword>
  <keyword>Acute Myocardial Infarction (AMI)</keyword>
  <keyword>Percutaneous Coronary Intervention (PCI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

